{"id":479545,"date":"2021-04-21T08:13:09","date_gmt":"2021-04-21T12:13:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/"},"modified":"2021-04-21T08:13:09","modified_gmt":"2021-04-21T12:13:09","slug":"nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/","title":{"rendered":"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>Loughborough, England, April  21, 2021  (GLOBE NEWSWIRE) &#8212; <\/strong>Nemaura Medical, Inc. (NASDAQ: NMRD) (\u201cNemaura\u201d or the \u201cCompany\u201d), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced will host a shareholder update call on Wednesday, April 28, 2021 at 4:30 pm ET.<\/p>\n<p>Participants are asked to pre-register for the call through the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YLRQ1Mld9tP5cDFgqx2wfKQpGiR56kz5PZZhuPFVuZ7m-g9aIWBgS7jbhDgONqP0Cc8hwFHKdVAQE8jG8j2xxe8Lmx-XmXhNKuN3brg9jicpW6dvHE4puYb9OpddvQFpO5pio6IL1OK1tfTOE80f7MgvjoJHynxATPl3pCb3LJs=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/dpregister.com\/sreg\/10154964\/e6da9faa78<\/a>.<\/p>\n<p align=\"justify\">Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without Internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (U.S. domestic), 1-412-317-5413 (international) or 0203 5143188 (United Kingdom, toll free). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Nemaura Medical call.<\/p>\n<p align=\"justify\">The conference call will also be available through a live webcast found <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FOdaj2mYmU5ySBoXigTKHa1xCCRBQVj0dpPwiAsLFUjFttz60ZMCNyYKjBOeoDtKyEW_RYRCYDzK2EUNjL3GLyyG_Dtb4JjgtJeQthaDwYOH8e6i8ANHFp8-VBnASjLKCPLZK8sKNnUOFTT6b1rdJQ==\" rel=\"nofollow noopener\" target=\"_blank\">h<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jEoBznQ2uiCntSeYbdovS6TtTczvICkYeB_e3qr7v2f0C5Po3H5E7KlsgXxq_CMeBOd8Tm325zd-xBA194BmbsIrWWA5eARPYeKnc1UfeQn0yBTAqgfA7iQFELjGf-J4mc7SrFRoCPvEguJaEK2g8A==\" rel=\"nofollow noopener\" target=\"_blank\">e<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FlxpRLLuAJchucW7p9yGfPCkVasWPZrY05UqmknXLHHhZim5ivKTbhjUbQ0ankkzuuHCnX-dDFrj-kDMWe0sa9tt2-s4agIHtqYv2Ihxj1neXbhLkRbKww2WhgO5W4XahhBxwuICDcsYV7O7P6ykZw==\" rel=\"nofollow noopener\" target=\"_blank\">re<\/a>.<\/p>\n<p align=\"justify\">A telephonic replay of the call will be available through May 6, 2021 and may be accessed by calling 1-877-344-7529 (U.S. domestic) or 1-412-317-0088 (international) and using access code 10154964.<\/p>\n<p align=\"justify\">Although there will be no live Q&amp;A session, management will address pre-submitted questions during the call. Those wishing to submit a question may do so via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xhcu8mOHBo91sUPNME_GUK_P-oMqzJLqx056vmOp1Ukv3z04lokfxXJK5RmjpB0SpA_d2hkCXDgj5tXihR5ssA==\" rel=\"nofollow noopener\" target=\"_blank\">brets@coreir.com<\/a> using the subject line \u201cConference Call Question Submission.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Nemaura Medical, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT<sup>\u00ae<\/sup> and proBEAT<sup>\u2122<\/sup>. sugarBEAT<sup>\u00ae<\/sup>, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT<sup>\u00ae<\/sup> to the U.S. FDA. proBEAT<sup>\u2122<\/sup> combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT<sup>\u00ae<\/sup>diabetes program.<\/p>\n<p align=\"justify\">The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rxhuabb2qfdckOlTkqNJu8xK-eh7C_j0U1qiJ2-NFDbA5kFd4RY4T796HV5EW0tVJZni7F2E-FSPxxjYxR35WdDHoef9_6Y6WVJJPJmGYfQ=\" rel=\"nofollow noopener\" target=\"_blank\">www.NemauraMedical.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Statement Regarding Forward-Looking Statements:<\/strong>\n      <\/p>\n<p align=\"justify\">The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT<sup>\u2122<\/sup> in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura\u2019s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners\u2019 ability to develop, market and sell proBEAT<sup>\u2122<\/sup>, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT<sup>\u2122<\/sup> digital health, and sugarBEAT<sup>\u00ae<\/sup>. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products\/services. The FDA reserves the right to re-evaluate their decision that proBEAT<sup>\u2122<\/sup> qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura\u2019s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>Jules Abraham<br \/>CORE IR<br \/>917-885-7378<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qsW3xR799GxXCavRBxnRm3r2L3a1h7VDcVnsWsPor4lF7zrTnyBwdQZpmWGOiN96Qjn2kPEBpOzU10Dd5fJYfQ==\" rel=\"nofollow noopener\" target=\"_blank\">julesa@coreir.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/fc385abb-0e63-4caa-9dab-2e9a95cb81dc\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Loughborough, England, April 21, 2021 (GLOBE NEWSWIRE) &#8212; Nemaura Medical, Inc. (NASDAQ: NMRD) (\u201cNemaura\u201d or the \u201cCompany\u201d), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced will host a shareholder update call on Wednesday, April 28, 2021 at 4:30 pm ET. Participants are asked to pre-register for the call through the following link: https:\/\/dpregister.com\/sreg\/10154964\/e6da9faa78. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without Internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (U.S. domestic), 1-412-317-5413 (international) or 0203 5143188 (United Kingdom, toll free). All callers should dial in approximately 10 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479545","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Loughborough, England, April 21, 2021 (GLOBE NEWSWIRE) &#8212; Nemaura Medical, Inc. (NASDAQ: NMRD) (\u201cNemaura\u201d or the \u201cCompany\u201d), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced will host a shareholder update call on Wednesday, April 28, 2021 at 4:30 pm ET. Participants are asked to pre-register for the call through the following link: https:\/\/dpregister.com\/sreg\/10154964\/e6da9faa78. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without Internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (U.S. domestic), 1-412-317-5413 (international) or 0203 5143188 (United Kingdom, toll free). All callers should dial in approximately 10 &hellip; Continue reading &quot;Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-21T12:13:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET\",\"datePublished\":\"2021-04-21T12:13:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/\"},\"wordCount\":739,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/\",\"name\":\"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw==\",\"datePublished\":\"2021-04-21T12:13:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/","og_locale":"en_US","og_type":"article","og_title":"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET - Market Newsdesk","og_description":"Loughborough, England, April 21, 2021 (GLOBE NEWSWIRE) &#8212; Nemaura Medical, Inc. (NASDAQ: NMRD) (\u201cNemaura\u201d or the \u201cCompany\u201d), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced will host a shareholder update call on Wednesday, April 28, 2021 at 4:30 pm ET. Participants are asked to pre-register for the call through the following link: https:\/\/dpregister.com\/sreg\/10154964\/e6da9faa78. Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without Internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (U.S. domestic), 1-412-317-5413 (international) or 0203 5143188 (United Kingdom, toll free). All callers should dial in approximately 10 &hellip; Continue reading \"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-21T12:13:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET","datePublished":"2021-04-21T12:13:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/"},"wordCount":739,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/","name":"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw==","datePublished":"2021-04-21T12:13:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDc3MyM0MTMxNDM5IzUwMDA3NzU0Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nemaura-medical-to-conduct-shareholder-update-call-april-28-2021-430pm-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479545"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479545\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}